

# Richard Platt

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3950836/richard-platt-publications-by-year.pdf>

**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58 papers	2,797 citations	23 h-index	52 g-index
60 ext. papers	3,272 ext. citations	9.7 avg, IF	4.86 L-index

#	Paper	IF	Citations
58	Effect of Mailing Educational Material to Patients With Atrial Fibrillation and Their Clinicians on Use of Oral Anticoagulants. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2214321	10.4	0
57	42. INSPIRE-ASP UTI Trial: A 59 Hospital Cluster Randomized Evaluation of INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection versus Routine Antibiotic Selection Practices for Patients with Urinary Tract Infection (UTI). <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S142-S143	1	
56	426. COVID-19 Infection Prevention Practices That Exceed CDC Guidance: Balancing Extra Caution Against Impediments to Care. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S313-S314	1	
55	When Can We Rely on Real-World Evidence to Evaluate New Medical Treatments?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	2
54	When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	5
53	When Are Treatment Blinding and Treatment Standardization Necessary in Real-World Clinical Trials?. <i>Clinical Pharmacology and Therapeutics</i> , <b>2021</b> ,	6.1	1
52	Is Learning Worth the Trouble? - Improving Health Care System Participation in Embedded Research. <i>New England Journal of Medicine</i> , <b>2021</b> , 385, 5-7	59.2	4
51	PCORnet <sup>2</sup> 2020: current state, accomplishments, and future directions. <i>Journal of Clinical Epidemiology</i> , <b>2021</b> , 129, 60-67	5.7	26
50	4. 137 Hospital Cluster-Randomized Trial of Mupirocin-Chlorhexidine vs Iodophor-Chlorhexidine for Universal Decolonization in Intensive Care Units (ICUs) (Mupirocin Iodophor Swap Out Trial). <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S3-S4	1	0
49	171. The Impact of COVID-19 on Healthcare-Associated Infections. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S102-S103	1	0
48	13. INSPIRE-ASP Pneumonia Trial: A 59 Hospital Cluster Randomized Evaluation of INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection versus Routine Antibiotic Selection Practices for Patients with Pneumonia. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S9-S10	1	
47	41. Assessing Past vs Present COVID-19 Infection: A Survey of Criteria for Discontinuing Precautions in Asymptomatic Patients. <i>Open Forum Infectious Diseases</i> , <b>2021</b> , 8, S29-S31	1	
46	Rethinking ethical oversight in the era of the learning health system. <i>Healthcare</i> , <b>2020</b> , 8, 100462	1.8	0
45	Considerations for using distributed research networks to conduct aspects of randomized trials. <i>Contemporary Clinical Trials Communications</i> , <b>2020</b> , 17, 100515	1.8	1
44	University of Pennsylvania 12th annual conference on statistical issues in clinical trials: Electronic health records in randomized clinical trials-challenges and opportunities (morning panel session). <i>Clinical Trials</i> , <b>2020</b> , 17, 405-413	2.2	
43	Using Healthcare Data in Embedded Pragmatic Clinical Trials among People Living with Dementia and Their Caregivers: State of the Art. <i>Journal of the American Geriatrics Society</i> , <b>2020</b> , 68 Suppl 2, S49-S54	5.6	4
42	The Emergence of Population Health in US Academic Medicine: A Qualitative Assessment. <i>JAMA Network Open</i> , <b>2019</b> , 2, e192200	10.4	15

41	How pharmacoepidemiology networks can manage distributed analyses to improve replicability and transparency and minimize bias. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2019</b> , 29, 3	2.6	18
40	Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory. <i>BMC Medical Research Methodology</i> , <b>2017</b> , 17, 144	4.7	79
39	Using a Handheld Device for Patient Data Collection: A Pilot for Medical Countermeasures Surveillance. <i>Public Health Reports</i> , <b>2016</b> , 131, 30-4	2.5	2
38	Objective Sepsis Surveillance Using Electronic Clinical Data. <i>Infection Control and Hospital Epidemiology</i> , <b>2016</b> , 37, 163-71	2	49
37	Potential Adverse Effects of Anesthesia in Children--Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 314, 409	27.4	2
36	Comparison of trends in sepsis incidence and coding using administrative claims versus objective clinical data. <i>Clinical Infectious Diseases</i> , <b>2015</b> , 60, 88-95	11.6	111
35	Improving documentation and coding for acute organ dysfunction biases estimates of changing sepsis severity and burden: a retrospective study. <i>Critical Care</i> , <b>2015</b> , 19, 338	10.8	38
34	Neurotoxicity of generic anesthesia agents in infants and children: an orphan research question in search of a sponsor. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1515-6	27.4	33
33	Four health data networks illustrate the potential for a shared national multipurpose big-data network. <i>Health Affairs</i> , <b>2014</b> , 33, 1178-86	7	83
32	Launching PCORnet, a national patient-centered clinical research network. <i>Journal of the American Medical Informatics Association: JAMIA</i> , <b>2014</b> , 21, 578-82	8.6	331
31	Algorithms for identification of Guillain-Barré Syndrome among adolescents in claims databases. <i>Vaccine</i> , <b>2013</b> , 31, 2075-9	4.1	17
30	Targeted versus universal decolonization to prevent ICU infection. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 2255-65	59.2	556
29	The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. <i>Transfusion</i> , <b>2012</b> , 52, 1363-78	2.9	8
28	The organizational structure and governing principles of the Food and Drug Administration's Mini-Sentinel pilot program. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21 Suppl 1, 12-7	2.6	44
27	The U.S. Food and Drug Administration's Mini-Sentinel program: status and direction. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21 Suppl 1, 1-8	2.6	121
26	The U.S. Food and Drug Administration's Mini-Sentinel Program. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 1-303	2.6	150
25	Risk of Guillain-Barré Syndrome after meningococcal conjugate vaccination. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2012</b> , 21, 1350-8	2.6	33
24	Time for a culture change?. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1464-5	59.2	13

23	Developing the Sentinel System--a national resource for evidence development. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 498-9	59.2	271
22	Cluster randomized trials in comparative effectiveness research: randomizing hospitals to test methods for prevention of healthcare-associated infections. <i>Medical Care</i> , <b>2010</b> , 48, S52-7	3.1	33
21	The new Sentinel Network--improving the evidence of medical-product safety. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 645-7	59.2	171
20	Cluster randomized trials to study the comparative effectiveness of therapeutics: stakeholders' concerns and recommendations. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2009</b> , 18, 554-61	2.6	13
19	Opportunity knocks: the electronic (public health) medical record. <i>Epidemiology</i> , <b>2009</b> , 20, 662-3	3.1	7
18	Comparing drug effectiveness at health plans: the ethics of cluster randomized trials. <i>Hastings Center Report</i> , <b>2008</b> , 38, 39-48	3.3	20
17	Active drug safety surveillance: a tool to improve public health. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2008</b> , 17, 1175-82	2.6	28
16	A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2008</b> , 17, 1226-34	2.6	35
15	Improving methicillin-resistant <i>Staphylococcus aureus</i> surveillance and reporting in intensive care units. <i>Journal of Infectious Diseases</i> , <b>2007</b> , 195, 330-8	7	93
14	Speed bumps, potholes, and tollbooths on the road to panacea: making best use of data. <i>Health Affairs</i> , <b>2007</b> , 26, w153-5	7	3
13	Real-time vaccine safety surveillance for the early detection of adverse events. <i>Medical Care</i> , <b>2007</b> , 45, S89-95	3.1	173
12	Cluster randomized trials: opportunities and barriers identified by leaders of eight health plans. <i>Medical Care</i> , <b>2007</b> , 45, S29-37	3.1	22
11	Syndromic surveillance using minimum transfer of identifiable data: the example of the National Bioterrorism Syndromic Surveillance Demonstration Program. <i>Journal of Urban Health</i> , <b>2003</b> , 80, i25-31	5.8	27
10	Gastric and duodenal safety of daily alendronate. <i>Archives of Internal Medicine</i> , <b>2002</b> , 162, 936-42		43
9	Multicenter epidemiologic and health services research on therapeutics in the HMO Research Network Center for Education and Research on Therapeutics. <i>Pharmacoepidemiology and Drug Safety</i> , <b>2001</b> , 10, 373-7	2.6	67
8	Bayesian inference on protective antibody levels using case-control data. <i>Biometrics</i> , <b>2001</b> , 57, 135-42	1.8	16
7	Erythromycin prolongs the QTc interval among patients with pneumonia. <i>Pharmacoepidemiology and Drug Safety</i> , <b>1997</b> , 6, 13-9	2.6	4
6	Surveillance for surgical site infections: the uses of antibiotic exposure. <i>Infection Control and Hospital Epidemiology</i> , <b>1994</b> , 15, 717-23	2	6

5	Effect of federally mandated education policies on prescribing of isotretinoin to women of childbearing age. <i>Pharmacoepidemiology and Drug Safety</i> , <b>1993</b> , 2, 217-221	2.6
4	Predictors of response to therapy for infections caused by <i>Pseudomonas aeruginosa</i> . <i>Clinical Infectious Diseases</i> , <b>1984</b> , 6 Suppl 3, S759-68	11.6
3	Pharmacovigilance in the HMO Research Network391-398	2
2	The HMO Research Network261-269	3
1	Health Maintenance Organizations/Health Plans163-188	10